Loading...

Fund Overview

Fund Size

Fund Size

₹1,208 Cr

Expense Ratio

Expense Ratio

2.14%

ISIN

ISIN

INF277K016A9

Minimum SIP

Minimum SIP

₹1,000

Exit Load

Exit Load

No Charges

Inception Date

Inception Date

28 Dec 2015

About this fund

Tata India Pharma & Healthcare Fund Regular Growth is a Sector - Healthcare mutual fund schemes offered by Tata Mutual Fund. This fund has been in existence for 8 years, 11 months and 6 days, having been launched on 28-Dec-15.
As of 03-Dec-24, it has a Net Asset Value (NAV) of ₹30.73, Assets Under Management (AUM) of 1208.05 Crores, and an expense ratio of 2.14%.
  • The fund's asset allocation comprises around 94.62% in equities, 0.00% in debts, and 5.38% in cash & cash equivalents.
  • You can start investing in Tata India Pharma & Healthcare Fund Regular Growth with a SIP of ₹1000 or a Lumpsum investment of ₹5000.

Portfolio Summaryas of 31st October 2024

Equity1,143.05 Cr94.62%
Others64.99 Cr5.38%

Top Holdings

All Holdings

Equity

Debt & Others

NameType sortAmount sortHoldings sort
Sun Pharmaceuticals Industries LtdEquity148.71 Cr12.31%
Aurobindo Pharma LtdEquity103.48 Cr8.57%
Lupin LtdEquity89.72 Cr7.43%
Dr Reddy's Laboratories LtdEquity78.31 Cr6.48%
Cipla LtdEquity76.04 Cr6.29%
Cash / Net Current AssetCash63.1 Cr5.22%
Divi's Laboratories LtdEquity61.82 Cr5.12%
Fortis Healthcare LtdEquity53.42 Cr4.42%
Zydus Lifesciences LtdEquity47.19 Cr3.91%
Alkem Laboratories LtdEquity43.49 Cr3.60%
Apollo Hospitals Enterprise LtdEquity41.37 Cr3.42%
Aster DM Healthcare Ltd Ordinary SharesEquity29.21 Cr2.42%
Ajanta Pharma LtdEquity29.03 Cr2.40%
Medi Assist Healthcare Services LtdEquity25.85 Cr2.14%
FDC LtdEquity25.76 Cr2.13%
Orchid Pharma LtdEquity25.51 Cr2.11%
HealthCare Global Enterprises LtdEquity25.47 Cr2.11%
Wockhardt LtdEquity23.37 Cr1.93%
Torrent Pharmaceuticals LtdEquity22.71 Cr1.88%
Ipca Laboratories LtdEquity22.63 Cr1.87%
Indoco Remedies LtdEquity20.7 Cr1.71%
Akums Drugs and Pharmaceuticals LtdEquity16.11 Cr1.33%
Piramal Pharma LtdEquity16.02 Cr1.33%
Jupiter Life Line Hospitals LtdEquity14.31 Cr1.18%
Sanofi India LtdEquity13.02 Cr1.08%
Laurus Labs LtdEquity12.53 Cr1.04%
Mankind Pharma LtdEquity11.06 Cr0.92%
Coromandel International LtdEquity10.01 Cr0.83%
Ami Organics LtdEquity9.89 Cr0.82%
Sanofi Consumer Healthcare India LtdEquity9.44 Cr0.78%
Syngene International LtdEquity9.21 Cr0.76%
Procter & Gamble Health LtdEquity8.37 Cr0.69%
Medplus Health Services LtdEquity7.92 Cr0.66%
GlaxoSmithKline Pharmaceuticals LtdEquity6.67 Cr0.55%
Deepak Nitrite LtdEquity4.72 Cr0.39%
A) RepoCash - Repurchase Agreement1.89 Cr0.16%

Allocation By Market Cap (Equity)

Large Cap Stocks

40.33%

Mid Cap Stocks

30.82%

Small Cap Stocks

21.35%

Other Allocation

Equity Sector

Debt & Others

SectorAmount sortHoldings sort
Healthcare1,118.43 Cr92.58%
Basic Materials24.62 Cr2.04%

Risk & Performance Ratios

Standard Deviation

This fund

15.14%

Cat. avg.

15.68%

Lower the better

Sharpe Ratio

This fund

0.91

Cat. avg.

0.87

Higher the better

Sortino Ratio

This fund

--

Cat. avg.

1.61

Higher the better

Fund Managers

MS

Meeta Shetty

Since March 2021

RS

Rajat Srivastava

Since September 2024

Additional Scheme Detailsas of 31st October 2024

ISIN
INF277K016A9
Expense Ratio
2.14%
Exit Load
No Charges
Fund Size
₹1,208 Cr
Age
8 years 11 months
Lumpsum Minimum
₹5,000
Fund Status
Open Ended Investment Company
Benchmark
Nifty Pharma TR INR

Investment ObjectiveInvestment Objective

To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.

Tax Treatment

iconCapital Gains Taxation:

iconDividend Taxation:

info icon

Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Similar Sector - Healthcare Funds

Fund nameExpense RatioExit LoadFund size
1Y
Motilal Oswal S&P BSE Healthcare ETF

Very High Risk

0.2%-₹28.64 Cr-
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth

Very High Risk

0.9%1.0%₹881.52 Cr-
Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth

Very High Risk

2.3%1.0%₹881.52 Cr-
Aditya Birla Sun Life Nifty Healthcare ETF

Very High Risk

0.2%-₹40.84 Cr-
ITI Pharma and Healthcare Fund Direct Growth

Very High Risk

0.5%1.0%₹208.21 Cr-
ITI Pharma and Healthcare Fund Regular Growth

Very High Risk

2.4%1.0%₹208.21 Cr-
Mirae Asset Healthcare Fund Direct Growth

Very High Risk

0.5%1.0%₹2770.21 Cr-
Mirae Asset Healthcare Fund Regular Growth

Very High Risk

1.9%1.0%₹2770.21 Cr-
Nippon India Nifty Pharma ETF

Very High Risk

0.2%-₹852.28 Cr-
Axis NIFTY Healthcare ETF

Very High Risk

0.3%-₹19.81 Cr-

About the AMC

Tata Mutual Fund

Tata Mutual Fund

Total AUM

₹1,88,167 Cr

Address

Mafatlal Centre, 9th Floor, Mumbai, 400 021

Other Funds by Tata Mutual Fund

Fund nameExpense RatioExit LoadFund size
1Y
Tata Silver ETF Fund of Fund Direct Growth

Very High Risk

0.1%0.0%₹72.09 Cr-
Tata Gold ETF Fund of Fund Direct Growth

High Risk

0.2%0.0%₹117.15 Cr-
Tata Fixed Maturity Plan Series 56 Scheme G Direct Growth

Low to Moderate Risk

-0.0%--
Tata Fixed Maturity Plan Series 56 Scheme H Direct Growth

Low to Moderate Risk

-0.0%--
Tata Fixed Maturity Series E Direct Growth

Low to Moderate Risk

-0.0%--
Tata Balanced Advantage Fund Direct Growth

High Risk

0.4%1.0%₹10288.08 Cr-
Tata Ultra Short Term Fund Direct Growth

Low to Moderate Risk

0.3%0.0%₹3817.50 Cr-
Tata Business Cycle Fund Direct Growth

Very High Risk

0.5%1.0%₹2885.41 Cr-
Tata Nifty India Digital ETF Fund of Fund Direct Growth

Very High Risk

0.1%1.0%₹86.29 Cr-
Tata Nifty SDL Plus AAA PSU Bond Dec 2027 60: 40 Index Fund Direct Growth

Low to Moderate Risk

0.2%0.0%₹858.78 Cr-
Tata Floating Rate Fund Direct Growth

Moderate Risk

0.3%0.0%₹168.32 Cr-
Tata Small Cap Fund Direct Growth

Very High Risk

0.3%1.0%₹9463.78 Cr-
Tata Large & Mid Cap Fund Direct Growth

Very High Risk

0.6%1.0%₹8390.40 Cr-
Tata Mid Cap Growth Fund Direct Growth

Very High Risk

0.7%1.0%₹4443.96 Cr-
Tata Hybrid Equity Fund Direct Growth

Very High Risk

1.0%1.0%₹4137.30 Cr-
Tata Ethical Fund Direct Growth

Very High Risk

0.7%0.0%₹3201.55 Cr-
Tata Gilt Securities Fund Direct Growth

Moderate Risk

0.3%0.0%₹933.89 Cr-
Tata Equity P/E Fund Direct Growth

Very High Risk

0.8%1.0%₹8681.31 Cr-
Tata Infrastructure Fund Direct Growth

Very High Risk

1.1%0.0%₹2451.22 Cr-
Tata Treasury Advantage Fund Direct Growth

Low to Moderate Risk

0.2%0.0%₹2667.51 Cr-
Tata Money Market Fund Direct Growth

Low to Moderate Risk

0.1%0.0%₹27059.75 Cr-
Tata Equity Savings Fund Direct Growth

Moderate Risk

0.5%0.0%₹215.99 Cr-
Tata Young Citizens Fund Direct Growth

Very High Risk

1.9%1.0%₹367.04 Cr-
Tata Liquid Fund Direct Growth

Moderate Risk

0.2%0.0%₹28348.53 Cr-
Tata Large Cap Fund Direct Growth

Very High Risk

1.0%1.0%₹2415.27 Cr-
Tata Retirement Savings Moderate Fund Direct Growth

Very High Risk

0.6%1.0%₹2161.97 Cr-
Tata Retirement Savings Conservative Fund Direct Growth

Moderately High risk

1.0%1.0%₹172.34 Cr-
Tata Short Term Bond Fund Direct Growth

Moderate Risk

0.4%0.0%₹2892.55 Cr-
Tata Retirement Savings Progressive Fund Direct Growth

Very High Risk

0.5%1.0%₹2088.63 Cr-
Tata Corporate Bond Fund Direct Growth

Moderate Risk

0.3%0.0%₹2752.59 Cr-
Tata India Consumer Fund Direct Growth

Very High Risk

0.7%0.0%₹2374.84 Cr-
Tata Digital India Fund Direct Growth

Very High Risk

0.4%0.0%₹11835.20 Cr-
Tata Banking & Financial Services Fund Direct Growth

Very High Risk

0.5%0.0%₹2374.28 Cr-
Tata Resources & Energy Fund Direct Growth

Very High Risk

0.6%0.0%₹1042.41 Cr-
Tata India Pharma & Healthcare Fund Direct Growth

Very High Risk

0.7%0.0%₹1208.05 Cr-
TATA Nifty G-SEC Dec 2029 Index Fund Direct Growth

Moderate Risk

0.1%0.0%₹178.27 Cr-
Tata Multi Asset Opportunities Fund Direct Growth

Very High Risk

0.5%1.0%₹3409.99 Cr-
Tata Flexi Cap Fund Direct Growth

Very High Risk

0.7%1.0%₹3008.93 Cr-
Tata Dividend Yield Fund Direct Growth

Very High Risk

0.7%1.0%₹994.96 Cr-
Tata Housing Opportunities Fund Direct Growth

Very High Risk

0.7%1.0%₹609.92 Cr-
Tata Arbitrage Fund Direct Growth

Low Risk

0.3%0.0%₹12432.45 Cr-
Tata Banking & PSU Debt Fund Direct Growth

Low to Moderate Risk

0.3%0.0%₹207.53 Cr7.0%
Tata Overnight Fund Direct Growth

Low Risk

0.1%0.0%₹4600.33 Cr-
Tata Nifty Midcap 150 Momentum 50 Index Fund Direct Growth

Very High Risk

0.4%0.0%₹632.70 Cr-
Tata CRISIL IBX Gilt Index-April 2026 Fund Direct Growth

Low to Moderate Risk

0.1%0.0%₹1069.63 Cr-
Tata Multicap Fund Direct Growth

Very High Risk

0.5%1.0%₹3218.66 Cr-
Tata Treasury Advantage Fund Segregated Portfolio 1 Direct Growth

Low to Moderate Risk

-0.0%--
Tata Medium Term Fund Segregated Portfolio 1 Direct Growth

Moderate Risk

-1.0%--
Tata Corporate Bond Fund Segregated Portfolio 1 Direct Growth

Moderate Risk

-0.0%--
TATA Nifty G-Sec Dec 2026 Index Fund Direct Growth

Low to Moderate Risk

0.2%0.0%₹107.77 Cr-

Risk Level

Your principal amount will be at Very High Risk

Very High Risk
Wealth Monitor

Unlock Expert Insights!

Maximise Returns with our Wealth Monitor App. Try it now!

Still got questions?
We're here to help.

The NAV of Tata India Pharma & Healthcare Fund Regular Growth, as of 03-Dec-2024, is ₹30.73.
The fund's allocation of assets is distributed as 94.62% in equities, 0.00% in bonds, and 5.38% in cash and cash equivalents.
The fund managers responsible for Tata India Pharma & Healthcare Fund Regular Growth are:-
  1. Meeta Shetty
  2. Rajat Srivastava